VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Class I HLA-A*0201-restricted gp100209-2M peptide vaccine
Vaccine Information
  • Vaccine Name: Class I HLA-A*0201-restricted gp100209-2M peptide vaccine
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Vaccine Ontology ID: VO_0007593
  • Type: peptide
  • Status: Research
  • Preparation: Seventy HLA-A*0201+ stage IIb–IV melanoma patients were vaccinated with class I HLA-A*0201-restricted gp100209-2M peptide and stratiļ¬ed for HLA-DP4 restriction. HLA-DP4+ patients were also vaccinated with class II HLA-DP4-restricted MAGE-3243-258 peptide. Patients from both groups were randomized to receive 2 doses of leuprolide or not (Vence et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Human Response

  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: Small increase in TREC-enriched CD8+CD45RA+RO-CD27+CD103+ but not in TREC-enriched CD4+CD45RA+ROCD31+ t-cell population. Igf-1 levels were not changed, moderate increase in IL-7 levels in th sera of all patients 6 weeks after vaccination. Increased expression of CD127 (IL-7 receptor-a) at week 24, compared with baseline, was only seen in the CD8+CD45RA+ROCD27+CD103+ T-cell population (Vence et al., 2013).
References
Vence et al., 2013: Vence LM, Wang C, Pappu H, Anson RE, Patel TA, Miller P, Bassett R, Lizee G, Overwijk WW, Komanduri K, Benjamin C, Alvarado G, Patel SP, Kim K, Papadopoulos NE, Bedikian AY, Homsi J, Hwu WJ, Boyd R, Radvanyi L, Hwu P. Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination. Journal of immunotherapy (Hagerstown, Md. : 1997). 2013; 36(4); 276-286. [PubMed: 23603862].